Avidity Biosciences, Inc.
US ˙ NasdaqGM ˙ US05370A1088

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael F MacLean. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael F MacLean has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RNA / Avidity Biosciences, Inc. Chief Financial Officer 65,806
US:VERV / Verve Therapeutics, Inc. Director 47,664
Chief Financial Officer 48,000
US:BIIB / Biogen Inc. SVP, Chief Accounting Officer 21,259
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael F MacLean. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases RNA / Avidity Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in RNA / Avidity Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RNA / Avidity Biosciences, Inc. Insider Trades
Insider Sales RNA / Avidity Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in RNA / Avidity Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-03-13 RNA MacLean Michael F 40,000 24.5190 40,000 24.5190 980,760 37 22.7300 -71,560 -7.30

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RNA / Avidity Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Michael F MacLean as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-15 2025-08-06 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -30,914 65,806 -31.96 42.73 -1,320,844 2,811,653
2025-03-21 2025-03-20 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -7,935 96,720 -7.58 31.06 -246,425 3,003,678
2025-01-23 2025-01-21 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -1,665 104,655 -1.57 28.59 -47,608 2,992,421
2025-01-23 2025-01-21 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -1,622 106,320 -1.50 28.59 -46,378 3,039,997
2025-01-08 2025-01-06 4 RNA Avidity Biosciences, Inc.
Common Stock
A - Award 25,000 107,942 30.14
2024-12-19 2024-12-18 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -11,151 82,942 -11.85 32.66 -364,192 2,708,886
2024-11-08 2024-11-06 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -13,875 94,093 -12.85 45.33 -629,008 4,265,603
2024-11-08 2024-11-06 4 RNA Avidity Biosciences, Inc.
Common Stock
M - Exercise X 13,875 107,968 14.75 6.57 91,159 709,350
2024-11-08 2024-11-06 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -65,182 94,093 -40.92 45.33 -2,954,954 4,265,603
2024-11-08 2024-11-06 4 RNA Avidity Biosciences, Inc.
Common Stock
M - Exercise X 65,182 159,275 69.27 8.82 574,905 1,404,806
2024-11-08 2024-11-06 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -27,262 94,093 -22.46 46.22 -1,260,017 4,348,866
2024-09-23 2024-09-23 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -11,510 96,355 -10.67 44.00 -506,440 4,239,620
2024-09-23 2024-09-19 4 RNA Avidity Biosciences, Inc.
Common Stock
A - Award 25,000 121,355 25.95
2024-09-23 2024-09-19 4 RNA Avidity Biosciences, Inc.
Common Stock
A - Award 25,000 121,355 25.95
2024-06-20 2024-06-18 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -11,228 57,865 -16.25 39.13 -439,345 2,264,223
2024-06-20 2024-06-17 4 RNA Avidity Biosciences, Inc.
Common Stock
A - Award 25,000 82,865 43.20
2024-06-20 2024-06-17 4 RNA Avidity Biosciences, Inc.
Common Stock
A - Award 25,000 82,865 43.20
2024-06-14 2024-06-12 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -104,245 44,093 -70.28 35.72 -3,723,141 1,574,795
2024-06-14 2024-06-12 4 RNA Avidity Biosciences, Inc.
Common Stock
M - Exercise X 104,245 148,338 236.42 8.82 919,441 1,308,341
2024-05-16 2024-05-14 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -75,000 44,093 -62.98 28.28 -2,121,045 1,246,976
2024-05-16 2024-05-14 4 RNA Avidity Biosciences, Inc.
Common Stock
M - Exercise X 75,000 119,093 170.10 8.82 661,500 1,050,400
2024-03-15 2024-03-13 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale -40,000 44,093 -47.57 24.52 -980,760 1,081,116
2024-03-15 2024-03-13 4 RNA Avidity Biosciences, Inc.
Common Stock
M - Exercise 40,000 84,093 90.72 8.82 352,800 741,700
2024-01-23 2024-01-22 4 RNA Avidity Biosciences, Inc.
Common Stock
S - Sale X -1,616 16,884 -8.74 10.13 -16,370 171,035
2024-01-23 2024-01-20 4 RNA Avidity Biosciences, Inc.
Common Stock
A - Award 22,500 27,209 477.81
2023-01-24 2023-01-20 4 RNA Avidity Biosciences, Inc.
Common Stock
A - Award 18,500 21,852 551.91
2022-03-15 2022-01-21 4 RNA Avidity Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 131,250 131,250
2021-06-21 2021-06-17 4 VERV Verve Therapeutics, Inc.
Stock Option (right to buy)
A - Award 47,664 47,664
2021-02-04 2021-02-02 4 RNA Avidity Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 92,000 92,000
2020-01-16 2020-01-15 4 AKCA AKCEA THERAPEUTICS, INC.
Common Stock
A - Award 28,000 48,000 140.00
2020-01-03 2020-01-02 4 AKCA AKCEA THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 57,000 57,000
2019-09-23 2019-09-19 4 AKCA AKCEA THERAPEUTICS, INC.
Common Stock
A - Award 20,000 20,000
2019-01-04 2019-01-02 4 AKCA AKCEA THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 83,000 83,000
2018-01-04 2018-01-02 4 AKCA AKCEA THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 30,000 30,000
2017-09-05 2017-08-31 4 AKCA AKCEA THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 332,708 332,708
2010-02-17 2010-02-12 4 BIIB BIOGEN IDEC INC.
Common Stock
F - Taxes -875 21,259 -3.95 55.21 -48,309 1,173,706
2010-02-17 2010-02-12 4 BIIB BIOGEN IDEC INC.
Common Stock
F - Taxes -1,127 22,134 -4.85 55.21 -62,222 1,222,015
2009-02-17 2009-02-12 4 BIIB BIOGEN IDEC INC.
Common Stock
F - Taxes -1,132 20,570 -5.22 52.61 -59,555 1,082,169
2009-02-17 2009-02-12 4 BIIB BIOGEN IDEC INC.
Common Stock
F - Taxes -875 21,702 -3.88 52.61 -46,034 1,141,724
2008-02-14 2008-02-12 4 BIIB BIOGEN IDEC INC.
Stock Option (right to buy)
A - Award 23,130 23,130
2008-02-14 2008-02-12 4 BIIB BIOGEN IDEC INC.
Common Stock
A - Award 8,260 27,326 43.32
2008-02-14 2008-02-12 4 BIIB BIOGEN IDEC INC.
Common Stock
F - Taxes -1,120 19,066 -5.55 60.56 -67,827 1,154,640
2007-02-14 2007-02-12 4 BIIB BIOGEN IDEC INC
Stock Option (right-to-buy)
A - Award 25,900 25,900
2007-02-14 2007-02-12 4 BIIB BIOGEN IDEC INC
Common Stock
A - Award 10,000 10,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)